![]() |
市场调查报告书
商品编码
1370622
过敏治疗市场 - 按治疗(抗过敏药物、免疫疗法)、类型(鼻炎、气喘、皮肤、食物、眼睛)、给药途径、配销通路、全球预测,2023 - 2032Allergy Therapeutics Market - By Treatment (Anti-allergy drug, Immunotherapy ), Type (Rhinitis, Asthma, Skin, Food, Eye), Route of Administration, Distribution Channel, Global Forecast, 2023 - 2032 |
2023年至2032年,全球过敏治疗市场的复合年增长率将达到6.6%。过敏(包括花粉热和食物过敏等呼吸道过敏)盛行率的不断上升,推动了对有效治疗的需求。过敏诊断和免疫治疗技术的进步改善了治疗结果,推动了业务成长。
人们对过敏及其对健康影响的认识不断增强,促使人们寻求医疗干预,这对市场扩张来说是个好兆头。此外,污染和气候模式变化等环境因素导致过敏发生率升高,为业务成长开闢了新的空间。
此外,支持性医疗政策、合作措施和新型过敏疗法的开发将进一步推动市场进步。赛诺菲公司于 2023 年 7 月宣布,已同意收购 Qunol,这是一家专门从事健康和保健行业的美国着名品牌。
市场根据治疗类型、类型、给药途径、配销通路和地区进行划分。
根据治疗类型,到2032 年,免疫疗法治疗领域的复合年增长率将达到7%,这是由于人们越来越认识到免疫疗法在解决过敏的根本原因、减轻症状严重程度和为患者提供长期缓解方面的有效性,从而推动业务发展这种治疗方式的成长。
根据类型,气喘细分市场在2023 年至2032 年期间将录得7.2% 的复合年增长率,原因包括气喘盛行率增加、气喘治疗研究的扩大以及针对气喘患者开发先进且更有针对性的治疗方法,从而推动了气喘市场的成长部分。
在整个分析期间,鼻内给药途径的复合年增长率为 6.8%。非侵入性治疗的便利性和患者偏好、鼻内给药在管理过敏症状方面的有效性以及鼻内过敏疗法的持续创新将推动该领域的成长。
从地区来看,在该地区过敏流行率不断上升和医疗基础设施不断完善的推动下,亚太地区过敏治疗行业在分析期内预计将以 7% 的复合年增长率增长。此外,患者意识的提高和对有效过敏治疗的需求不断增长将促进该地区的业务成长。
The global allergy therapeutics market will showcase a 6.6% CAGR from 2023 to 2032. The increasing prevalence of allergies, including respiratory allergies like hay fever and food allergies, drives demand for effective treatments. Advancements in allergy diagnostics and immunotherapy techniques have improved treatment outcomes, driving business growth.
A growing awareness of allergies and their impact on health prompts individuals to seek medical intervention will bode well for the market expansion. Moreover, environmental factors like pollution and changing climate patterns lead to a higher incidence of allergies, opening a new scope for business growth.
Additionally, supportive healthcare policies, collaborative initiatives and the development of novel allergy therapeutics will further drive the market progress. Sanofi SA announced in July 2023 that it had agreed to acquire Qunol, a prominent U.S.-based brand specializing in the health and wellness industry.
The market is segregated based on treatment type, type, route of administration, distribution channel, and region.
Based on treatment type, the immunotherapy treatment segment will exhibit a 7% CAGR through 2032, driven by the increasing recognition of immunotherapy's effectiveness in addressing the root causes of allergies, reducing symptom severity, and providing long-term relief to patients, thus driving business growth for this treatment modality.
Based on type, the asthma segment will record 7.2% CAGR during 2023-2032, driven by factors such as increasing prevalence of asthma, expanding research in asthma therapeutics, and the development of advanced and more targeted treatments for asthma patients, fueling growth in the segment.
The intranasal route of administration segment will depict a 6.8% CAGR throughout the analysis period. The convenience and patient preference for non-invasive treatments, the effectiveness of intranasal delivery in managing allergic symptoms, and continuous innovation in intranasal allergy therapies will drive growth in the segment.
Regionally, the Asia Pacific allergy therapeutics industry is estimated to grow at a 7% CAGR during the analysis timeline, driven by the region's increasing prevalence of allergies and rising healthcare infrastructure. Moreover, the expanding patient awareness and growing demand for effective allergy treatments will foster business growth in the region.